Endometrial receptivity assay (ERA)

Taiwan IVF Group is proud to be the first IVF center in Taiwan to offer the latest infertility treatment: Endometrial receptivity assay (ERA) Endometrial receptivity assay (ERA) is used to assess endometrial status and to determine whether the patient’s endometrium had a receptive gene profile or not at the time in which the biopsy has been performed. The analysis reveals the timing of the implantation window and leads to a personalised embryo transfer (pET) timing based on the individual results obtained. The result from the test will determine if a woman is receptive or not in the day and kind of cycle in which the biopsy has been performed. If she is receptive, it means that her window of implantation is placed in the day in which the biopsy was performed and therefore the blastocyst could implant during this day and kind of cycle. A non receptive result could imply a displaced window of implantation. Therefore, a second biopsy would be needed in order to validate this displacem...

It is a state-of-the-art diagnostic method, which was developed and patented by IVIGEN after more than 10 years of research. This technic allows to evaluate, from a molecular point of view, the status of the endometrial receptivity. ERA indicates the window of implantation (WOI), increasing your chances of successful transfer The endometrial receptivity is the status in which the endometrium is ready for embryo implantation to take place. This occurs around days 19-21 in each menstrual cycle of a fertile woman. Until now, the only study done on the endometrium was an ultrasound scan, and there was not analysis method available to help doctors in their clinical practice.